FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3192144779> ?p ?o ?g. }

• W3192144779 endingPage "608" @default.
• W3192144779 startingPage "602" @default.
• W3192144779 abstract "Multiple myeloma (MM) is an incurable hematologic malignancy, and outcomes remain poor for patients with triple-class relapsed/refractory MM (RRMM). Descriptive analyses were performed on available data for patient characteristics, disease course, and outcomes of the KCd on triple-class RRMM patients at our institution.Twenty-three patients with triple-class RRMM treated with KCd between June 2017 and October 2020 were included in our analysis. The regimen KCd consisted of 28 days cycles of carfilzomib 20/36 mg/m2 IV on days 1, 2, 8, 9, 15, and 16, cyclophosphamide 300 mg/m2 IV weekly, and dexamethasone (20-40) mg orally weekly.Patients received a median of 6 (3-10) prior regimens. The median number of cycles administered was 4 (1-11) cycles. Overall response rate was 52%, 6 patients (26%) achieved very good partial response (VGPR), 6 patients (26%) achieved partial response (PR), and 5 patients (22%) achieved stable disease (SD). Progression-free survival (PFS) and Overall-survival (OS) were 4 and 11.9 months, respectively. There was no reported treatment-related mortality. The most common grade ≥3 adverse events were neutropenia (26%), thrombocytopenia (56.5%), and anemia (56.5%).KCd showed clinically meaningful efficacy and manageable safety profile in patients with triple-class RRMM in real-world." @default.
• W3192144779 created "2021-08-16" @default.
• W3192144779 creator A5008376636 @default.
• W3192144779 creator A5015261180 @default.
• W3192144779 creator A5016471127 @default.
• W3192144779 creator A5025325121 @default.
• W3192144779 creator A5039680248 @default.
• W3192144779 creator A5042487436 @default.
• W3192144779 creator A5051992190 @default.
• W3192144779 creator A5052064208 @default.
• W3192144779 creator A5057629728 @default.
• W3192144779 creator A5060120424 @default.
• W3192144779 creator A5082036221 @default.
• W3192144779 creator A5088949367 @default.
• W3192144779 date "2021-08-31" @default.
• W3192144779 modified "2023-10-17" @default.
• W3192144779 title "Carfilzomib, cyclophosphamide, and dexamethasone (KCd) for the treatment of triple‐class relapsed/refractory multiple myeloma (RRMM)" @default.
• W3192144779 cites W1570622790 @default.
• W3192144779 cites W2089311432 @default.
• W3192144779 cites W2144728882 @default.
• W3192144779 cites W2749746182 @default.
• W3192144779 cites W2921533600 @default.
• W3192144779 cites W2969931905 @default.
• W3192144779 cites W2970009779 @default.
• W3192144779 cites W2970922094 @default.
• W3192144779 cites W2979640690 @default.
• W3192144779 cites W2995934717 @default.
• W3192144779 cites W2997301227 @default.
• W3192144779 cites W3013063217 @default.
• W3192144779 cites W3083612548 @default.
• W3192144779 cites W3094871979 @default.
• W3192144779 cites W3094996259 @default.
• W3192144779 cites W3120855064 @default.
• W3192144779 cites W3130050285 @default.
• W3192144779 cites W3133229959 @default.
• W3192144779 cites W3172041393 @default.
• W3192144779 cites W4211191410 @default.
• W3192144779 doi "https://doi.org/10.1111/ejh.13697" @default.
• W3192144779 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34378251" @default.
• W3192144779 hasPublicationYear "2021" @default.
• W3192144779 type Work @default.
• W3192144779 sameAs 3192144779 @default.
• W3192144779 citedByCount "7" @default.
• W3192144779 countsByYear W31921447792022 @default.
• W3192144779 countsByYear W31921447792023 @default.
• W3192144779 crossrefType "journal-article" @default.
• W3192144779 hasAuthorship W3192144779A5008376636 @default.
• W3192144779 hasAuthorship W3192144779A5015261180 @default.
• W3192144779 hasAuthorship W3192144779A5016471127 @default.
• W3192144779 hasAuthorship W3192144779A5025325121 @default.
• W3192144779 hasAuthorship W3192144779A5039680248 @default.
• W3192144779 hasAuthorship W3192144779A5042487436 @default.
• W3192144779 hasAuthorship W3192144779A5051992190 @default.
• W3192144779 hasAuthorship W3192144779A5052064208 @default.
• W3192144779 hasAuthorship W3192144779A5057629728 @default.
• W3192144779 hasAuthorship W3192144779A5060120424 @default.
• W3192144779 hasAuthorship W3192144779A5082036221 @default.
• W3192144779 hasAuthorship W3192144779A5088949367 @default.
• W3192144779 hasConcept C121332964 @default.
• W3192144779 hasConcept C126322002 @default.
• W3192144779 hasConcept C141071460 @default.
• W3192144779 hasConcept C142424586 @default.
• W3192144779 hasConcept C2776063141 @default.
• W3192144779 hasConcept C2776364478 @default.
• W3192144779 hasConcept C2776694085 @default.
• W3192144779 hasConcept C2776755627 @default.
• W3192144779 hasConcept C2777063308 @default.
• W3192144779 hasConcept C2780108899 @default.
• W3192144779 hasConcept C2780401358 @default.
• W3192144779 hasConcept C2781413609 @default.
• W3192144779 hasConcept C71924100 @default.
• W3192144779 hasConcept C87355193 @default.
• W3192144779 hasConcept C90924648 @default.
• W3192144779 hasConceptScore W3192144779C121332964 @default.
• W3192144779 hasConceptScore W3192144779C126322002 @default.
• W3192144779 hasConceptScore W3192144779C141071460 @default.
• W3192144779 hasConceptScore W3192144779C142424586 @default.
• W3192144779 hasConceptScore W3192144779C2776063141 @default.
• W3192144779 hasConceptScore W3192144779C2776364478 @default.
• W3192144779 hasConceptScore W3192144779C2776694085 @default.
• W3192144779 hasConceptScore W3192144779C2776755627 @default.
• W3192144779 hasConceptScore W3192144779C2777063308 @default.
• W3192144779 hasConceptScore W3192144779C2780108899 @default.
• W3192144779 hasConceptScore W3192144779C2780401358 @default.
• W3192144779 hasConceptScore W3192144779C2781413609 @default.
• W3192144779 hasConceptScore W3192144779C71924100 @default.
• W3192144779 hasConceptScore W3192144779C87355193 @default.
• W3192144779 hasConceptScore W3192144779C90924648 @default.
• W3192144779 hasIssue "6" @default.
• W3192144779 hasLocation W31921447791 @default.
• W3192144779 hasLocation W31921447792 @default.
• W3192144779 hasOpenAccess W3192144779 @default.
• W3192144779 hasPrimaryLocation W31921447791 @default.
• W3192144779 hasRelatedWork W1985864219 @default.
• W3192144779 hasRelatedWork W2093665884 @default.
• W3192144779 hasRelatedWork W2515748752 @default.
• W3192144779 hasRelatedWork W2519443088 @default.
• W3192144779 hasRelatedWork W2892083382 @default.

• next